Illumina Inc. (Nasdaq: ILMN) Thursday announced that Dr. Robert S. Epstein, M.D., has joined the company’s board of directors.
He is an epidemiologist who worked in public health and academia before joining the private sector.
From 2010 to 2012, Epstein was chief R&D officer and president of Medco-UBC, a 2,400-person global research organization focused on conducting personalized medicine, health economics, drug safety, outcomes and comparative effectiveness research on behalf of the biopharmaceutical, medical device and diagnostics industries.
Prior to this role, Epstein was Medco’s chief medical officer for 13 years, where he led formulary development, clinical guideline development, drug information services, personalized medicine program development, and client analytics and reporting.
In addition, he is the former president of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) and has served on the board of directors of the Drug Information Association (DIA) and the International Society of Quality of Life.
Epstein has published more than 75 peer-reviewed medical articles and book chapters, and serves as a reviewer for several influential medical journals, including the "New England Journal of Medicine" and "JAMA."